A RNA vaccine for stage 2-3 triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have stage 2 or 3 triple-negative breast cancer that has been confirmed by biopsy.
- If you received pembrolizumab (Keytruda) before, you must have completed it.
- Have good enough organ function (kidney, liver, bone marrow) as shown by blood tests.
- Not have serious heart problems, like a recent heart attack, uncontrolled irregular heartbeat, or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a targeted therapy (olaparib) and chemotherapy (paclitaxel) before surgery for people with an aggressive type of early breast cancer called triple-negative breast cancer. It is for those whose tumors have a specific genetic feature called HRD-positive, which may make the cancer more sensitive to these treatments.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.